The Native Antigen Company (NAC) has released a highly purified mycoplasma pneumoniae (M.pneumoniae) native antigen.
According to the company, M.pneumoniae is recognised as one of the most common causes of community-acquired pneumonia.
Early diagnosis of M.pneumoniae, usually by an ELISA IgM assay, is important because the infection often responds well to appropriate antibiotics.
However, ELISA assays, particularly those for IgM detection, often exhibit poor sensitivity and may be susceptible to cross reactivity from other pathogens.
The company claims that its new purified antigen preparation, which is highly reactive to IgM, will offer in-vitro diagnostic (IVD) manufacturers the opportunity to introduce next-generation ELISA assays that demonstrate greater specificity set against an inherently low background signal.
